Did You Know...
...that the Eveready Battery began as an invention called the "electric flowerpot," which was a tube with a battery and light bulb inside? The idea was to fasten this gizmo to the side of a flowerpot so it would illuminate the flowers from the bottom. The idea died on the vine and the businessman who licensed the flower pot, Conrad Huber, was left with a pile of useless tubes -- until he found a way to market them as batteries to light the world!
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8022227 | Method of synthesizing 1-indazole compounds A method is provided for synthesizing 1H-indazole compounds in which aromatic carbonyl compounds are reacted with a nitrogen source to form oximes which are then converted to 1H-indazoles. ... | 09/20/2011 |
| 8008506 | Indazole compounds Provided are compounds represented by the following formula (A-1) and formula (1), or salts thereof. The compounds of formula (A-1) and formula (1) or salts thereof have β3 adrenergic receptor agonist activity, and thus are useful as therapeutic and prophylactic ag... | 08/30/2011 |
| 7847104 | Process for the preparation of indazolyl ureas that inhibit Vanilloid subtype1 (VR1) receptors The present invention relates to a process of preparing indazolyl ureas that are useful as antagonists of the vanilloid receptor subtype 1 (VR1). ... | 12/07/2010 |
| 7825261 | Indazole compounds This invention relates to indazole compounds of formula (I) or (II) shown below. Each variable in formula (I) or (II) is defined in the specification. These compounds can be used to treat cancer. ... | 11/02/2010 |
| 7825260 | Aminopropanol derivatives as sphingosine-1-phosphate receptor modulators Compounds of formula I, wherein X, a, b, R1, R2, R3, R4 and R5 are as defined in the specification, processes for their production, their uses and pharmaceutical compos... | 11/02/2010 |
| 7601847 | Preparation and purification of 4-(indazol-3-yl)phenols The present invention concerns processes for the production and purification of compounds of the formula: where R1-R10 are as defined in the specification. Preferred processes of the invention utilize ... | 10/13/2009 |
| 7439262 | Substituted 1-alkylamino-1-H-indazoles for the treatment of glaucoma Substituted 1-alkylamino-1H-indazoles for lowering intraocular pressure and treating glaucoma are disclosed. ... | 10/21/2008 |
| 7432266 | Phosphodiesterase 4 inhibitors Selective PDE4 inhibition is achieved by aryl and heteroaryl pyrazole compounds. The compounds exhibit improved PDE4 inhibition as compared to compounds such as rolipram and show selectivity with regard to inhibition of other classes of PDEs. ... | 10/07/2008 |
| 7414132 | Opioid receptor antagonists A compound of the formula (I); wherein the variables X1 to X10, R1 to R7 including R3′, E, W, v, y, z, A and B are as described, or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereom... | 08/19/2008 |
| 7410992 | Ophthalmic compositions for treating ocular hypertension This invention relates to potent potassium channel blocker compounds of Formula (I) or a formulation thereof for the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient. This invention also relates to the ... | 08/12/2008 |
| 7378532 | Fused pyrazolyl compound A fused pyrazolyl compound of the following formula: wherein A, Ar1, Ar2, R1, R2, R3, and R4, are as defined herein. Also disclosed is a pharmaceutical compo... | 05/27/2008 |
| 7375113 | Nitrogenous fused-ring derivatives, medicinal compositions containing the derivatives, and use thereof as drugs The present invention provides nitrogen-containing fused-ring derivatives represented by the following general formula, or pharmaceutically acceptable salts thereof, or prodrugs thereof, which exhibit an excellent inhibitory activity in human SGLT and are useful as ... | 05/20/2008 |
| 7365211 | Heterocyclic GABAA subtype selective receptor modulators This invention relates to a method for modulating α2 subtype GABAA receptors with heterocyclic compounds of formula I, and salts, solvates and prodrugs thereof. The invention further relates to said heterocyclic compounds and pharmaceutical co... | 04/29/2008 |
| 7354944 | Thiadiazole compounds and methods of use The invention relates to thiadiazole compounds useful for treating diseases mediated by protein kinase B (PKB). The invention also relates to the therapeutic use of such thiadiazole compounds and compositions thereof in treating disease states associated with abnorm... | 04/08/2008 |
| 7338972 | Substituted 1-alkylamino-1H-indazoles for the treatment of glaucoma Substituted 1-alkylamino-1H-indazoles for lowering intraocular pressure and treating glaucoma are disclosed. ... | 03/04/2008 |
| 7332149 | Vitronectin receptor antagonist pharmaceuticals The present invention describes novel compounds of the formula: (Q)d—Ln—Ch, useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient... | 02/19/2008 |
| 7321045 | Vitronectin receptor antagonist pharmaceuticals The present invention describes novel compounds of the formula: (Q)d-Ln-Ch, useful for the diagnosis and treatment of cancer, methods of imaging tumors in a patient, and methods of treating cancer in a patient. Th... | 01/22/2008 |
| 7304060 | Indazolyl-substituted pyrroline compounds as kinase inhibitors The present invention is directed to novel indazolyl-substituted pyrroline compounds of Formula (I): useful as kinase or dual-kinase inhibitors, methods for producing such compounds and methods for treating or am... | 12/04/2007 |
| 7300950 | Pyrazole derivatives, their preparation and their use in pharmaceuticals The present invention relates to pyrazole derivatives of the formula I, their preparation and their use in pharmaceuticals: in which X, R1, R1a, R2, R3, R4 a... | 11/27/2007 |
| 7291744 | N-ureidoalkyl-amino compounds as modulators of chemokine receptor activity The present application describes modulators of chemokine receptors of formula (I): or pharmaceutically acceptable salt forms thereof, useful for the prevention of asthma and other allergic diseases. ... | 11/06/2007 |
| 7276516 | CB1 antagonist compounds Novel compounds of structural formula (I) are disclosed. As modulators of the Cannabinoid-1 (CB1) receptor, these compounds are useful in the treatment, prevention and suppression of diseases mediated by the CB1 receptor. As such, compounds of the present invention ... | 10/02/2007 |
| 7271180 | 1-Aryl-or 1-alkylsulfonylbenzazole derivatives as 5-hydroxytryptamine-6 ligands The present invention provides a compound of formula I and the use thereof for the therapeutic treatment of disorders relating to or affected by the 5-HT6 receptor ... | 09/18/2007 |
| 7271190 | Indazole compounds as β3 adrenoceptor agonist A compound represented by the general formula I: I wherein R1 represents hydrogen, etc. R2 represents NHSO2R3, etc., provided that R3 represents C1-6 alkyl, etc. R5 represents hydrogen, etc. R6 | 09/18/2007 |
| 7259183 | Indole, indazole and indoline derivatives as CETP inhibitors The present invention relates to compounds of formula (I): wherein —X—Y—, R1 to R11 and n are as defined in the description and claims, and pharmaceutically acceptable salts thereof. T... | 08/21/2007 |
| 7250436 | Indazole-aminoacetonitrile derivatives having special pesticidal activity The invention relates to compounds of the general formula wherein Ar1, Ar2, R4, R5, R6, R7, R8, W, X, a and b have the significances gi... | 07/31/2007 |
| 7241791 | Substituted 4-(indazol-3-yl)phenols This invention provides compound of formulae I or II having the structure wherein R1, R2, R3, R4, R5, R6, R7, R8 | 07/10/2007 |
| 7226930 | Phosphodiesterase 4 inhibitors Selective PDE4 inhibition is achieved by aryl and heteroaryl pyrazole compounds. The compounds exhibit improved PDE4 inhibition as compared to compounds such as rolipram and show selectivity with regard to inhibition of other classes of PDEs. ... | 06/05/2007 |
| 7217728 | Diaminopropionic acid derivatives A compound of formula 1a which is useful for treating reperfusion injury, and salts, prodrugs, and related compounds. ... | 05/15/2007 |
| 7214699 | Indazole derivatives as CRF antagonists This invention relates to compounds which are generally CRF-1 receptor antagonists and which are represented by Formula I or Formula II: wherein R3 is optionally substituted aryl or heteroaryl, R1... | 05/08/2007 |
| 7211594 | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith This invention is generally directed to Indazole Derivatives having the following structure: or pharmaceutically acceptable salt thereof, wherein R1, R2 and A are as defined herein. Such com... | 05/01/2007 |
| 7208513 | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith Compounds having activity as selective inhibitors of JNK are disclosed. The compounds of this invention are indazole derivatives having the following structure: wherein R1, R2 and A are as d... | 04/24/2007 |
| 7199147 | Rho kinase inhibitors A compound represented by the formula (1): wherein R1—X— indicates that 1 to 4 R1—X— groups are present which may be the same or different, the rin... | 04/03/2007 |
| 7196082 | Ophthalmic compositions for treating ocular hypertension This invention relates to potent potassium channel blocker compounds of Formula I or a formulation thereof for the treatment of glaucoma and other conditions which leads to elevated intraoccular pressure in the eye of a patient. This invention also relates to the us... | 03/27/2007 |
| 7153881 | Compounds acting as melanocortin receptor ligands The present invention provides novel compounds and use of compounds of general formula (I) as ligands to the melanocortin receptors and/or for treatment of disorders in the melanocortin system: Wherein X and Y are independently chosen from O, N, S and (CH2 | 12/26/2006 |
| 7148054 | Evolution of whole cells and organisms by recursive sequence recombination The invention provides methods employing iterative cycles of recombination and selection/screening for evolution of whole cells and organisms toward acquisition of desired properties Examples of such properties include enhanced recombinogenicity, genome copy number,... | 12/12/2006 |
| 7141587 | Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use Indazole compounds that modulate and/or inhibit the activity of certain protein kinases are described. These compounds and pharmaceutical compositions containing them are capable of mediating tyrosine kinase signal transduction and thereby modulate and/or inhibit un... | 11/28/2006 |
| 7135575 | P38 inhibitors and methods of use thereof This invention relates to inhibitors of p38, and methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing the inhibitors and pharmaceutical compositions in the... | 11/14/2006 |
| 7112553 | Pesticidal indazole or benzotriazole derivatives A compound of formula (I) wherein G is either (i) or (ii), where M1 or M2 is bonded to A; n is 0 or 1; when G is (i), D is S, NR7, CR8═CR9, CR8═N, CR8═N(O), N═CR9 or N(O)... | 09/26/2006 |
| RE39265 | Heteroarylpiperidines, and their use as antipsychotics and analgetics Heteroarylpiperidines, pyrrolidines, and piperazines are useful as antipsychotic and analgesic agents. The compounds are especially useful for treating psychoses by administering to a mammal a psychoses-treating effective amount of one of the compounds. The compound... | 09/05/2006 |
| 7101884 | Tyrosine kinase inhibitors The present invention relates to compounds which inhibit, regulate and/or modulate tyrosine kinase signal transduction, compositions which contain these compounds, and methods of using them to treat tyrosine kinase-dependent diseases and conditions, such as angiogen... | 09/05/2006 |
